GSK-J4 hydrochloride | 2259

Cell-permeable. An ethyl ester derivative of the JMJD3 selective histone demethylase inhibitor GSK-J1 (Cat. No. 2260-1, 5) (IC₅₀> 50 μM in vitro. When administered to human primary macrophages, GSK-J4 can reduce lipopolysaccharide (LPS)-induced proinflammatory cytokine production, most notably including that of TNFα (IC₅₀ = 9 µM).

GSK-J4 is an ethyl ester derivative of the JMJD3-selective histone demethylase inhibitor GSK-J1 (Cat. No. 2260-1, 5) (IC₅₀> 50 μM in vitro).

2259 | GSK-J4 hydrochloride DataSheet

Alternate Name/Synonyms: Ethyl 3-​((6-​(4,​5-​dihydro-​1H-​benzo[d]azepin-​3(2H)-​yl)-​2-​-(pyridin-2- yl)pyrimidin-4-yl)amino)propanoate, monohydrochloride

Appearance: White to off-white solid

Formulation: N/A

CAS Number: N/A

Structure Available?: Yes

Peptide sequence: No

Salt Form: No

Molecular Formula: C₂₄H₂₇N₅O₂ ∙ HCl

Molecular Weight: 454

Cell-Permeable?: Yes

Purity: ≥95%

Solubilities: DMSO

Handling: Protect from light and mositure

Country of Origin: USA

Tag Line: Histone demethylase JMJD3/UTX inhibitor

MDL Number: N/A

PubChem CID: N/A

SMILES: N/A

InChi: N/A

InChi Key: N/A